马来酸曲美布汀联合抗抑郁焦虑药物治疗肠易激综合征疗效观察

目的：评价马来酸曲美布汀联合抗抑郁焦虑药物（黛力新、艾司唑仑）治疗肠易激综合征（IBS）的疗效。方法：将75例肠易激综合征患者随机分为两组,治疗组采用马来酸曲美布汀联合黛力新、艾司唑仑治疗,对照组单用马来酸曲美布汀治疗,疗程均为4周。治疗前后进行消化道症状、SDS和HAMA量表评分。结果：治疗组消化道症状积分、SDS和HAMA量表评分下降显著高于对照组。治疗组总有效率为86.8%,对照组为54.1%,两组比较,差异有统计学意义（P〈0.05）。结论：使用马来酸曲美布汀、黛力新、艾司唑仑联合治疗能有效缓解肠易激综合征（IBS）的症状。

Clinical observation on Trimebutine maleate combined Deanxit treated patients with irritable bowel syndrome

Objective：To evaluate the effect of trimebutine maleate combined with deanxit and estazolam in the treatment of patients with irritable bowel syndrome. Methods：75 cases of IBS were randomly divided into 2 groups,the treatment group took trimebutine maleate combined with deanxit and estazolam,and the control group only took trimebutine maleate. The time of the treatment was 4 weeks. The gastrointestinal symptoms scores,SDS and HAMA were used for evaluation before and after treatment. Results：The gastrointestinal symptoms scores,SDS and HAMA declined evidently in the treament group compared with the control group. The total efficacy rate was 86.8% in the treament group and 54.1% in the control group. The diffirence of the two groups had statistical significance （P0.05）. Conclusion：It is assumed that the treatment with trimebutine maleate combined with deanxit and estazolam could ameliorate the symptom of IBS efficiently.